Gold prices steady ahead of Fed decision, Trump’s tariff deadline
Omeros Corporation (NASDAQ:OMER), currently valued at $182 million, held its 2025 Annual Meeting of Shareholders on Friday. The meeting comes at a challenging time for the company, with InvestingPro data showing the stock trading near its 52-week low after falling nearly 70% year-to-date. According to a statement based on a recent SEC filing, shareholders voted on several matters, including the election of directors, an advisory vote on executive compensation, and the ratification of the company’s independent auditor.
Shareholders elected Arnold C. Hanish and Rajiv Shah, M.D., as Class I directors. Both will serve until the 2028 Annual Meeting of Shareholders or until their successors are elected and qualified. Hanish received 16,033,755 votes in favor, 1,245,397 against, and 279,370 abstentions. Shah received 16,198,053 votes in favor, 946,241 against, and 414,228 abstentions. There were 25,167,461 broker non-votes for each director nominee.
An advisory resolution regarding the compensation of Omeros’ named executive officers was also approved. The vote tally showed 15,086,368 shares in favor, 1,856,643 against, and 615,511 abstentions, with 25,167,461 broker non-votes.
In addition, shareholders ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The ratification received 41,204,073 votes in favor, 1,237,033 against, and 284,877 abstentions.
A total of 42,725,983 shares, representing 72.92% of the 58,592,713 shares entitled to vote, were represented at the meeting in person or by proxy.
This information is based on a press release statement and details disclosed in the company’s SEC filing.
In other recent news, Omeros Corporation reported a net loss of $33.5 million for the first quarter of 2025, which aligned with analyst expectations. Despite the losses, the company reduced its total debt by $10 million, reflecting strategic financial management. Omeros also announced the resubmission of its Biologics License Application for narsoplimab to the U.S. Food and Drug Administration, with a target action date of September 25, 2025. The company has submitted a Marketing Authorization Application to the European Medicines Agency for narsoplimab, a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy. This submission includes data showing a 61% response rate and a three-fold improvement in overall survival compared to a control group. H.C. Wainwright maintained its Buy rating on Omeros, citing potential approvals in both the U.S. and EU markets as key drivers for future growth. The firm also noted that approval could enhance the company’s other pipeline programs. Omeros continues to focus on strategic initiatives to support the commercial launch of narsoplimab, targeting key transplant centers for its introduction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.